Inherent Dangers of Using Non-US Food and Drug Administration-Approved Substances of Abuse.
J Clin Pharmacol
; 61 Suppl 2: S129-S141, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1355875
ABSTRACT
Use of US Food and Drug Administration-approved substances of abuse has innate risks due to pharmacologic and pharmacokinetic properties of the medications, but the risk when using nonapproved drug products is much greater. Unbeknownst to the user, the dose of active ingredients in substances of abuse can vary substantially between different products because of manufacturing practices or improper storage. Even naturally occurring substances of abuse can have extensive dosage variability because of effects of the growing season and conditions, or differences in harvesting, storage, or manufacture of the finished products. Many illicit substances are adulterated, to make up for intentional underdosing or to enhance the effect of the intended active ingredient. These adulterants can be dangerous and produce direct cardiovascular, neurologic, hematologic, or dermatologic reactions or obscure adverse effects. Finally, an illicit substance can be contaminated or substituted for another one during its manufacture, leading to differences in adverse events, adverse event severity, or the drug interaction profile. Substances can be contaminated with microbes that induce infections or heavy metals that can damage organs or cause cancer. This milieu of undisclosed substances can also induce drug interactions. For reasons that are discussed, individuals who use substances of abuse are at increased risk of morbidity or mortality if they develop coronavirus disease 2019. Health professionals who treat patients with acute, urgent events associated with substances of abuse, or those treating the chronic manifestations of addiction, need to appreciate the complex and variable composition of substances of abuse and their potential health effects.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Illicit Drugs
/
Substance-Related Disorders
/
Drug-Related Side Effects and Adverse Reactions
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
J Clin Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
Jcph.1860
Similar
MEDLINE
...
LILACS
LIS